Showing 481-490 of 18069 results for "".
Managing Diabetes & COVID-19 in the Wintertime
https://reachmd.com/programs/diabetes-discourse/managing-diabetes-covid-19-in-the-wintertime/12061/How are clinicians going above and beyond to keep patients with diabetes safe from COVID-19 and other threats during the winter months?The Potential of Statins to Prevent Diabetic-Related Blindness
https://reachmd.com/programs/diabetes-discourse/the-potential-of-statins-to-prevent-diabetic-related-blindness/6337/Retinopathy is one of the most common complications for patients living with diabetes but there are few treatment options and no early-stage interventions. How is research helping to pinpoint potential targets for early intervention and a possible oral treatment? Join host Dr. Steven Edelman and hisHot Topics in Diabetes: What Endocrinologists are Talking About
https://reachmd.com/programs/primary-care-today/hot-topics-diabetes-what-endocrinologists-are-talking-about/7571/Dr. Brian McDonough welcomes Dr. Tina Thethi, Assistant Professor of Medicine in the section of Endocrinology and Metabolism at Tulane University Health Sciences Center. Dr. Thethi provides the inside scoop on diabetes topics of particular interest to endocrinologists in practice today, from pre-diaDiabetes Research: Hope for a Cure in Stem Cells?
https://reachmd.com/programs/diabetes-discourse/diabetes-research-hope-for-a-cure-in-stem-cells/6008/Current stem cell therapy research is leading the way into producing functional pancreatic, insulin-producing cells. How will this translate into clinical trials and human therapy for diabetes from a scale, delivery and efficacy position? Join host Dr. Steven Edelman and his guest Dr. Emmanuel BaetgWhy Hybrid Closed-Loop Insulin Therapy Should Be Offered to Pregnant T1D Patients
https://reachmd.com/programs/diabetes-discourse/why-hybrid-closed-loop-insulin-therapy-should-be-offered-to-pregnant-t1d-patients/16256/A recent study concluded that hybrid closed-loop insulin therapy should be offered to all pregnant patients with type 1 diabetes. Here’s why.How I Treat IgA Nephropathy: Lessons From the Case Files
https://reachmd.com/programs/kdigo-conversations-nephrology/title-how-i-treat-iga-nephropathy-lessons-from-the-case-files/37117/Join Dr. Dana Rizk (University of Alabama at Birmingham) as she leads a thought-provoking discussion on applying the updated KDIGO guidelines for IgA nephropathy (IgAN) treatment. She is joined by 2 distinguished guests: Dr. Gaia Coppock (University of Pennsylvania School of Medicine) and Dr. AndreConference Coverage Highlights: American Diabetes Association
https://reachmd.com/programs/conference-coverage/conference-coverage-highlights-american-diabetes-association/4638/Join us for research highlights from the American Diabetes Association's 69th Scientific Sessions. This meeting took place June 5th through 9th, in New Orleans.Sodium-Glucose Transporters: A New Class of Diabetes Medications
https://reachmd.com/programs/diabetes-discourse/sodium-glucose-transporters-a-new-class-of-diabetes-medications/4804/SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive area for the treatment of diabetes. Join host Dr. Steven Edelman and his guest, professor of medicine at Tulane University,Diabetes Health Care Disparities in the African American Community
https://reachmd.com/programs/diabetes-discourse/diabetes-health-care-disparities-in-the-african-american-community/6647/Host Dr Farhad Zangeneh welcomes James R. Gavin III, MD, PhD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Together they will explore the trends in the growth of diabetes in African Americans, the policies needed to addressWeighing Metformin's Benefits & Risks in Patients With Renal Insufficiency
https://reachmd.com/programs/focus-on-diabetes/weighing-metformins-benefits-risks-in-patients-with-renal-insufficiency/6086/Metformin is often the first line of therapy for patients with type 2 diabetes: it is relatively inexpensive, available, and has proven efficacy. However, metformin is contraindicated for patients with renal insufficiency, a common comorbidity in diabetes. Do the benefits of metformin outweigh the r